Vabametkib Drug Asset Due Diligence Report 2026

This Vabametkib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Vabametkib can convert its Small molecule drug profile and c-Met biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Vabametkib (query alias: Vabametkib)
Modality / target	Small molecule drug; c-Met; c-Met inhibitors
Highest global status	Phase 2
Originator	ABION, Inc.
Active developers	ABION, Inc.

The MCP disease footprint includes Advanced Malignant Solid Neoplasm, Non-Small Cell Lung Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05882292	Phase 2	Recruiting	20	Primary endpoint not disclosed in English source
KCT0008450	Phase 2	Not yet recruiting	20	Primary endpoint not disclosed in English source
NCT05541822	Phase 2	Recruiting	178	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A phase 2 multicenter, open-label, parallel cohort study to evaluate the efficacy, safety, and pharmacokinetic profile of ABN401 in patients with advanced solid tumors harboring c-MET dysregulation.

Phase 2; n=42; evaluation: Positive. Reported fields: ORR(BICR) = 55.0 % ; ORR(BICR) = 52.0 %

Vabametkib in MET exon 14 skipping non-small-cell lung cancer: Efficacy and safety from the open-label, phase 2, cohort-1 trial.

Phase 2; n=40; evaluation: Positive. Reported fields: ORR = 43.2 % ( 27.10 - 60.51); mPFS = 6.2 Month ( 5.9 - NA)

Vabametkib plus lazertinib shows promising antitumor activity in advanced NSCLC with MET amplification resistant to 3rd-gen EGFR-TKIs

Phase 2; n=not disclosed; evaluation: Not stated in English source. Reported fields: Anti-tumor efficacy = 96.6 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Vabametkib addresses Advanced Malignant Solid Neoplasm, Non-Small Cell Lung Cancer. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 78 matched transaction record(s) under the scope “target-level comparable: c-Met.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: c-Met records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-04-17	Transaction title not available in English source	Approved	Financial terms not disclosed
2026-02-26	Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics	Preclinical	Financial terms not disclosed
2025-12-16	Transaction title not available in English source	Phase 3	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Mesylate salts of triazolopyrazine derivatives”. The milestone feed surfaced a patent-application signal described as “Novel maleate salts of triazolopyrazine derivatives, compositions, methods of use, and processes of manufacturing the same”. The milestone feed surfaced a patent-application signal described as “Composition for Modified release capsule containing triazolopyrazine derivatives compounds, binder and disintegrant”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO